...
首页> 外文期刊>Memórias do Instituto Oswaldo Cruz >Abnormal humoral immune response to influenza vaccination in pediatric type-1 human immunodeficiency virus infected patients receiving highly active antiretroviral therapy
【24h】

Abnormal humoral immune response to influenza vaccination in pediatric type-1 human immunodeficiency virus infected patients receiving highly active antiretroviral therapy

机译:接受高活性抗逆转录病毒治疗的小儿1型人类免疫缺陷病毒感染患者对流感疫苗的体液免疫反应异常

获取原文
   

获取外文期刊封面封底 >>

       

摘要

Given that highly active antiretroviral therapy (HAART) has been demonstrated useful to restore immune competence in type-1 human immunodeficiency virus (HIV-1)-infected subjects, we evaluated the specific antibody response to influenza vaccine in a cohort of HIV-1-infected children on HAART so as to analyze the quality of this immune response in patients under antiretroviral therapy. Sixteen HIV-1-infected children and 10 HIV-1 seronegative controls were immunized with a commercially available trivalent inactivated influenza vaccine containing the strains A/H1N1, A/H3N2, and B. Serum hemagglutinin inhibition (HI) antibody titers were determined for the three viral strains at the time of vaccination and 1 month later. Immunization induced a significantly increased humoral response against the three influenza virus strains in controls, and only against A/H3N2 in HIV-1-infected children. The comparison of post-vaccination HI titers between HIV-1+ patients and HIV-1 negative controls showed significantly higher HI titers against the three strains in controls. In addition, post vaccination protective HI titers (defined as equal to or higher than 1:40) against the strains A/H3N2 and B were observed in a lower proportion of HIV-1+ children than in controls, while a similar proportion of individuals from each group achieved protective HI titers against the A/H1N1 strain. The CD4+ T cell count, CD4/CD8 T cells ratio, and serum viral load were not affected by influenza virus vaccination when pre- vs post-vaccination values were compared. These findings suggest that despite the fact that HAART is efficient in controlling HIV-1 replication and in increasing CD4+ T cell count in HIV-1-infected children, restoration of immune competence and response to cognate antigens remain incomplete, indicating that additional therapeutic strategies are required to achieve a full reconstitution of immune functions.
机译:鉴于已证明高活性抗逆转录病毒疗法(HAART)可用于恢复感染1型人类免疫缺陷病毒(HIV-1)的受试者的免疫能力,因此我们评估了一组HIV-1-对流感疫苗的特异性抗体反应在HAART上感染儿童,以分析接受抗逆转录病毒治疗的患者这种免疫应答的质量。用市售的含有A / H1N1,A / H3N2和B株的三价灭活流感疫苗对16例受HIV-1感染的儿童和10例HIV-1血清阴性对照进行免疫。确定了血清血凝素抑制(HI)抗体滴度接种时和1个月后接种了3株病毒。在对照组中,免疫接种诱导了针对三种流感病毒株的体液应答的显着增加,而在感染HIV-1的儿童中,仅针对A / H3N2。 HIV-1 +患者和HIV-1阴性对照的疫苗接种后HI滴度比较显示,与对照组中的三种菌株相比,HI滴度明显更高。此外,在HIV-1 +儿童中,针对A / H3N2和B株的疫苗接种后保护性HI滴定度(等于或高于1:40)在HIV-1 +儿童中的比例低于对照组,而个体中的比例相似每组中的A / H1N1菌株均达到保护性HI滴度。当比较疫苗接种前和疫苗接种后的值时,CD4 + T细胞计数,CD4 / CD8 T细胞比例和血清病毒载量不受流感病毒疫苗接种的影响。这些发现表明,尽管HAART可以有效控制HIV-1感染儿童的HIV-1复制并增加其CD4 + T细胞计数,但免疫能力的恢复和对同源抗原的应答仍不完全,这表明还有其他治疗策略。需要完全重建免疫功能。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号